Clinical and Radiographic Success of MTA vs Biodentine

Recruiting now · Phase 4

Conditions studied: Indirect Pulp Cap, Pulpotomy

In brief

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Key facts

Study ID

NCT04863222

Run by

Geisinger Clinic

People needed

646

Starts

2021-11-12

Expected to finish

2026-12-01

Last updated by the study team

2025-12-23

Who can join

Age: 2 and older, up to 12. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female patients ages of 2 to ≤12 years.
• Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
• Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
• Parents of patients who can provide consent in English.
• Patients who need treatment in an operating room setting at Geisinger.

You may not qualify if…

• Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.
• Radiographs not displaying furcation region of the tooth.
• Patients with cardiac conditions who need prophylaxis for infective Endocarditis.
• Patients with any type of cancer in the past or present.
• Non-restorable molars.

Where it is running

• Geisinger — Danville, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.